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  The best management of large, diffuse or inflammatory breast cancers is uncertain 
and the place of radiotherapy and/or surgery is not clearly defined. 
Methods. 
 A cohort of 123 patients with non-metastatic locally advanced or inflammatory breast 
cancer 3 cm or more in diameter or T4, was treated between 1989 and 2006.   All 
patients received primary chemotherapy followed by radiotherapy, 40 Gy in 15 
fractions with 10 Gy boost. Patients with ER positive tumours received Tamoxifen.   
Assessment was carried out 8 weeks post-treatment and surgery was reserved for 
residual or recurrent disease. 
Results.  
 For each stage there were T2/3: 63, T4b: 31 and T4d: 29 patients.  80 had complete 
clinical response (65%) but 18 patients were never free of inoperable local disease.   25 
patients had residual operable disease at assessment and 12 patients who initially had a 
complete response developed operable local recurrence (LR).  37 patients (30%) had 
surgery at a mean of 15 months post diagnosis.    At 5 years, overall survival (OS) of 
the two surgical groups was not significantly different from those 68 patients who had 
complete remission without surgery, p=0.218  HR 1.46 (0.80-2.55). Surgery as an 
independent variable to predict survival was not significant on a Cox proportional 
hazards model (p=0.97) 
.  LR in the surgical groups was 13.5% v. 17.5% in the non-surgical patients. The 
median OS was 64.5 months and disease free survival (DFS) was 52.5 months.  5-year 





  In patients with a complete or partial response to chemo-radiotherapy for locally 
advanced or inflammatory breast cancer, reserving surgery for those with residual or 
recurrent local disease did not appear to compromise survival.  This finding would 
support examination of this treatment strategy by a randomised controlled trial 
Keywords 




Neo-adjuvant chemotherapy has become an acceptable standard of care for the 
management of locally advanced and inflammatory breast cancer in the expectation 
that the downsized tumour may be more amenable to breast conserving surgery.1   Post 
operative radiotherapy is then recommended to reduce the risk of local recurrence. 
There has also been a trend to treat primary breast cancers of 3 cm or more in  
diameter with primary chemotherapy especially where the lesion is Grade III, heavily 
node positive or in a young woman, although this may not improve the outcome.2    
Pre-operative chemotherapy increases the rate of breast conserving surgery3 but 
complete pathological remission remains low and this may not improve overall 
survival 2,4,5 although one long-term study does show survival benefit.6 
  For inflammatory breast cancer there is general agreement that surgery is not 
appropriate primary treatment but mastectomy and post-operative radiotherapy have 
been recommended when there has been a complete response to chemotherapy.7 
 
However, %RQDGRQQD¶VJURXSLQUHSRUWHGD randomised trial of chemotherapy 
followed by surgery or radiotherapy in locally advanced breast cancer and found no 
 4 
difference in the outcome 8 and there are several subsequent reports of primary chemo-
radiotherapy in the management locally advanced and inflammatory tumours.9,10,11 
The combination of chemotherapy and radiotherapy, given either concurrently or 
sequentially, is now the standard of care for locally advanced cancer of the naso & 
oropharynx12, oesophagus13, cervix14 and anal canal15 with subsequent salvage surgery 
where necessary. There are a number of studies in breast cancer patients where 
radiotherapy has been given in combination with chemotherapy but any subsequent 
surgery has been reserved for those cases with residual or recurrent local disease.16   
This latter management strategy, although unconventional in the management in breast 
cancer has been followed in this breast unit and the outcome of a cohort of patients 
with large, diffuse or inflammatory tumours, treated with primary sequential 
chemotherapy, radiotherapy and hormone therapy is presented.                                               
 
Method 
The period of study was from January 1st 1989 to June 31st 2006.  Patients were 
identified from the prospective breast unit database with near complete follow up, and 
further data were sourced from the oncology, and pathology databases, as well as the 
case notes.  Ethical approval was obtained for the retrospective study. 
Patients with a biopsy proven invasive breast cancer were clinically staged according 
to the TNM classification.   Those patients with a tumour 3 cm or more in diameter 
(T2/3) or had a diffuse (T4b) or an inflammatory carcinoma (T4d) and whose clinical 
node status was N0 or N1, were treated with primary chemo-radiotherapy.  Axillary 
node status was determined by clinical examination, NX.     Those who presented with 
metastatic disease or who developed metastases within 3 months of diagnosis were 
excluded from the study. 
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Patients received chemotherapy according to the local protocol at the time.   In the 
early part of the study 4 patients received a CMF regime, cyclophosphamide 
500mg/m2, 5 FU 500mg/m2 & methotrexate 35mg/m2  intravenously on day 1 & 8 with 
a 28 day cycle.  All subsequent patients received an anthracycline based 
chemotherapy, with either  six cycles of AC, cyclophosphamide 600mg/m2 & 
adriamycin 60 mg/m2 with a 21 day cycle or FEC(75), 5FU 600mg/m2, epirubicin 75 
mg/m2 & cyclophosphamide 600mg /m2 with a 21 day cycle.  Nine patients received 
only 4 cycles of AC.    Following chemotherapy, radiotherapy was administered, 
tailored to the individual patient.  The majority of patients received a total dose of 40 
Gy in 15 fractions over 3 weeks with a mini-tangent boost to the tumour site of 10Gy 
in 10 fractions in 1 week. The axilla was included with the breast fields as per local 
protocol but the supraclavicular fossa was not irradiated routinely. From 1989 all 
patients were simulated for treatment planning and CT simulation was used from 2001.  
3D planning and IMRT were not routinely used within the study period but the 
planning techniques were considered standard UK practice at the time.   All patients 
with ER positive tumours were treated with adjuvant tamoxifen with the exception of 
two postmenopausal women who received an aromatase inhibitor.   Three patients with 
ER negative tumours and 5 with unknown receptor status also received tamoxifen.   
Four pre-menopausal patients received goserelin in addition to tamoxifen.   No patient 
received trastuzumab as primary therapy which was not available at the time of the 
study.  At 6 to 8 weeks following completion of treatment, patients were assessed 
clinically and radiologically by mammography and ultrasound examination, and with 
typically 6 ultrasound or clinically guided biopsies of the tumour site.   When there 
was no residual tumour on imaging, multiple freehand core biopsies were taken from 
the site in the breast of the original tumour.   Patients then underwent three monthly 
follow-up with clinical examination and annual radiological surveillance.   Delayed 
 6 
primary surgery was reserved for residual disease at the time of treatment assessment 
or for patients who subsequently developed local recurrence which was amenable to 
operative intervention.       
 
Statistical Methods 
Overall and disease-free survival was calculated by the Kaplan-Meier method and 
compared by the log rank test, (MedCalc, Schoonjans 2005).  Potential prognostic 




There were 123 female patients and the mean age at presentation was 50.6 
years (range 27-73).  The mean and age ranges for the tumour stages were T2: 51.4, 
(35-72), T3: 48.1, (27-71), T4b: 51.5, (33-65), T4d: 53.5, (28-73).  There were only 12 
patients over the age of 65 (10%).    Over the same period 2652 patients with breast 
cancer were treated with a mean and median age of 62.  The tumour characteristics are 
shown in Table 1. The mean length of follow up of the 55 survivors was 103 months 
and the mean follow-up of all cases was 71 months.   
Eighty patients were apparently free of systemic and local disease at post-
treatment assessment (65%) but of these, 24 subsequently developed local recurrence 
of whom 12 were operable and were treated by delayed surgery at a mean of 27.7 
months (median 20).  Sixty-eight patients had a complete clinical remission (55%) and 
were managed without surgery, apart from one patient who requested prophylactic 
mastectomy with complete pathological remission. Fig.1.   
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 Core biopsy by protocol was not carried out in 29 patients (25%) and the 
absence of residual disease relied on clinical examination and imaging.  Thirty-eight 
patients (33%) were found to have residual disease on post-treatment core biopsy and a 
further 5 had evidence of progressive disease.  Of these 43 patients, 18 had progressive 
inoperable disease and 25 patients had operable residual disease and underwent   
subsequent primary surgery, 4 by wide local excision and the remainder by 
mastectomy at a mean of 9.2 months (median 9 months) post diagnosis.    Local 
recurrence in the surgical groups was 13.5% v. 17.6% in non-surgical patients.  
Concurrent regional recurrence was respectively 2.7% v. 4.4%. Fig.1  
Eight patients (6.5%) died with uncontrolled local disease, four of whom had 
an inflammatory cancer, T4d and two a diffuse tumour T4b.  Seven of these patients 
had progressive disease from the outset but one initially had a complete clinical 
remission 
    Overall survival at 5 years was 54%, median 64.5 months and recurrence-free 
survival was 43%, median 52.5 months.  Survival analysis following local treatment 
failure and salvage surgery (n=37) showed no significant difference in overall survival 
between those patients who had surgery for residual local disease at post-treatment 
assessment (n=25) and those with subsequent recurrent disease (n=12). p=0.646 HR 
1.31 95% CI.  (0.42-3.95). Fig 2. There was no significant overall survival advantage 
to those patients treated by surgery compared with those who had a complete clinical 
remission and no operation (n=68) p=0.218 HR 1.47 (0.81-2.55). Fig 3, or in disease 
free survival p=0.18 HR 1.49 (0.84-2.55).  Those patients with inoperable progressive 
disease at post treatment assessment (n=18) had poor overall survival, 11% at 5 years. 
Fig 4.   On comparison of those patients with (37) or without (86) salvage surgery, the 
tumour stage, grade, age, node and ER status were similar.  A Cox proportional 
hazards model which excluded those patients with progressive disease, was used to 
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assess whether surgery could be viewed as an independent variable to predict survival 
but the result was not significant (p=0.97).   
There was no significant difference in survival in patients who were clinically 
node positive (n=44) compared with those who were node negative (n=79) p = 0.28 
95% C.I.  (0.4-1.3). Pathological node status was not available.  (pNx: n=123)  
Survival in patients who were oestrogen receptor (ER) positive (49%) was 
significantly improved compared with those who were ER negative p=0.028  HR 1.79 
CI (1.06-3.13).  Patients with Grade III tumours (57%) had a marginally worse 
survival than those with Grade II tumours but this was not statistically significant.   
P=0.076, HR 0.61, 95% CI (0.36-1.05). 
  There was no significant difference in survival by T-stage, T2/T3 v T4  
p=0.29  HR 0.775  CI (0.48-1.25).   Fig 7.  T2 v T3  p=0.114  HR 1.73 CI (0.86- 3.78).   
T4b v T4d  p= 0.96 HR 1.01 CI (0.52-1.95). Fig 5b.    Patients aged less than 40, 
(n=21) showed no difference in survival from older patients.  p=0.47 HR 1.25 CI 
(0.66-2.45) or on age by decade. 
Of 68 deaths, 58 were certified as due to breast cancer, 6 as not due to breast cancer 







The aim of this study was to assess the outcome of patients treated with primary 
sequential chemo-radiotherapy, and to assess the role that any subsequent surgery 
played in maintaining local control of the disease.  Primary chemoradiotherapy is now 
 9 
standard practice for tumours of the nasopharynx, oesophagus, cervix and anus 12-15 
with reservation of surgery for residual or recurrent disease and this policy may be 
adopted for some rectal cancers.17 Many breast cancers are sensitive to chemotherapy 
and or radiotherapy and yet this treatment modality is not widely used.  
The number of patients is relatively small but over the period of study confidence in 
this unconventional treatment strategy gradually increased.  In the early years breast 
referrals to the unit were lower and latterly the incidence of locally advanced breast 
cancer appears to have fallen with the advent of the screening programme in the UK 
which started in 1988. 
The complete clinical remission rate of 65% in patients with locally advanced or 
inflammatory breast cancer after chemo-radiotherapy is higher than would be expected 
after neo-adjuvant chemotherapy alone. However  if all patients had had immediate 
surgical treatment post therapy, as would be the case with neo-adjuvant chemotherapy, 
the remission rate would probably have been lower since some of the post treatment 
core biopsies may have been false negative.  Subsequent local recurrences would have 
been apparent at earlier stage as residual disease. Nevertheless, if all 24 subsequent 
local recurrences are taken as residual disease the complete remission rate would have 
been 45% in this poor-risk group of patients. 
 
  .  The locoregional recurrence rate of 13.5% in the surgical patients and 17.5% in the 
non-surgical group is high but no more than would be expected from a recent large 
study.18    86 patients (70%) avoided any surgery although of these 12 had a local 
recurrence which was not amenable to subsequent salvage surgery.  It is therefore 
possible that as many as twelve patients (10%) may have been disadvantaged by the 
lack of primary surgery.  Against this must be considered the poor prognosis of this 
group of patients with locally advanced disease, half of whom had diffuse or 
 10 
inflammatory tumours 7, 19,20,21,22,23 and as expected, the greatest risk to overall survival 
was the progression to metastatic disease rather than local recurrence. There was no 
evidence of survival benefit from surgery on multivariate analysis and there is 
therefore no support from this study for surgery having an independent effect on 
survival.  
  Walshe21 has suggested that inflammatory breast cancer is a distinct disease entity  
although Montagna et al23 found no difference in recurrence free or overall survival 
between inflammatory and non-inflammatory breast cancer,   Another large study from 
the MD Anderson22 reported that that the outcome from inflammatory cancers was 
significantly worse and this finding has been supported by a subsequent analysis of 
SEER data.24  There was no significant difference in outcome in the present study 
when such   tumours were compared with those which were designated as advanced on 
the basis of size  and although there was a trend for the diffuse and inflammatory 
cancers to fare worst the difference was not significant 24 patients had T2 tumours 3 to 
5cm in diameter which were nevertheless judged to be locally advanced on clinical 
grounds.  This small group had a non-significantly worse outcome than those with T3 
tumours (Fig 5b)    
The lack of a significant difference in survival on the basis of node status might be 
unexpected but only 27 patients were operated on and the pathological node status of 
the cohort was therefore not available. Clinical evaluation of the axilla is well 
recognized to be a poor determinant of node status and ultrasound examination with 
needle biopsy of any suspicious node was not practiced at the time of this study.  
Given that the tumours were advanced, many of the patients who were rated Clinically 
N0 (NX) would in fact have been Pathological N1 with an expected worse survival.   
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 The EORTC trial10 showed that the best outcome from neoadjuvant therapy was in the 
group given chemotherapy, radiotherapy and hormone treatment, as in the present 
study but aromatase inhibitors and trastuzumab were not available at this time.  Data 
from the more recent NOAH study has shown that trastuzumab increased event free 
survival in this group of patients.25   There was a survival advantage for ER positive 
tumours but the difference in outcome between histological Grade 2 and less well 
differentiated Grade 3 tumours was not significant.  Smoot et al20 found that 
premenopausal status and palpable axillary nodes predicted poor survival in 
inflammatory breast cancer but Gajdos et al2 found these trends non significant.   In the 
present study the only positive prognostic factor was the oestrogen receptor status but 
the numbers in all these observational studies are relatively small and the risk of a type 
II error for negative findings is high. 
 
In an observational study of neoadjuvant chemotherapy followed by either surgery or 
radiotherapy from the Royal Marsden 11 there was no difference in survival although 
there was a non-significant increase in local recurrence in the radiotherapy group.  In 
the present study there has been no local recurrence in those patients having surgery 
for residual disease after chemoradiotherapy but this has not impacted on survival.  A 
meta-analysis16 of nine randomised trials of neoadjuvant versus adjuvant chemotherapy 
also shows an increased rate of local recurrence (LR) in patients treated by 
neoadjuvant therapy.  It is apparent that this effect was due to non-randomised 
radiotherapy without surgery in those patients with complete clinical remission in the 
neoadjuvant groups and this trend was most marked in three trials.3, 9, 26  It was 
concluded that neoadjuvant chemoradiotherapy should not be used without subsequent 
surgery.   However, we have found that provided the breast is carefully monitored and 
surgery is confined to those with residual or recurrent disease, that overall survival is 
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not compromised and the incidence of uncontrolled LR is relatively low.      There was 
a high mastectomy rate for residual disease in the present study 21/25 (84%) but at 
least two trials have found that conservative surgery in this situation leads to a high 
local recurrence rate with a secondary mastectomy rate of circa 20%.3,9  The 
hypofractionation of the radiotherapy was unconventional at the time of this study but 
the safety of this treatment regime has subsequently been confirmed.27  
 The overall survival of the patients who had subsequent surgery for local treatment failure 
was not significantly better than the majority with a complete remission (Fig. 4) and there 
was no disadvantage to those with a delayed operation for recurrent disease (Fig.2).  In a 
non-randomised observational study this non-significant finding should be viewed with 
caution but it does give some reassurance that delay in offering surgery does not appear to 
disadvantage patients with residual or recurrent disease, a policy which is supported by the 
long-term results from the Institut Curie(28)                               
With an overall 5-year survival rate of 54% comparable to the published literature, 29, 
30
 the use of primary combined chemotherapy, radiotherapy and endocrine treatment 
has been shown to provide effective treatment for locally advanced breast cancer.  
However, the optimal treatment of this disease remains uncertain and the need for 
further clinical studies is clear18,31 The present  findings  from a careful surveillance 
policy,  where the use of surgery was reserved for the treatment of residual disease or 
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Table 1.       Tumour Characteristics. 
  
Fig.1            Treatment Outcome of the Cohort. 
 
 
Fig.2            Surgery for Residual v Recurrent Disease 
 
 
Fig.3            Overall Survival: Surgery v No Surgery  
 
 
Fig.4            Survival of Total Cohort. 
 
 










                                                          Table 1. 
                                     Tumour Characteristics (n=123) 
 
Tumour       Number of Cases 
   T2 > 3 cm 
   T3 > 5 cm 
   T4b diffuse (peau d'orange) 





Clinical Node Status 
                   No 
                   N1 
                   pNx (AJCC) 
Distant metastasis 







Grade          I 
                   II 
                  III 





ER Status   +ve 
                   -ve 





         Invasive ductal ca. 
         Invasive lobular ca. 
         Mixed IDC /ILC. 
         Carcinosarcoma                                      
         Medullary ca. 
         NR                              
 
                     101 
                     14 
                      3 
      3 
                      1 
                      1 
 
 
























































                                                                     Fig. 1 
 
Treatment Outcome of Cohort of Patients with Locally 
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               Fig. 3                 Overall Survival: Surgery v  No Surgery 
 
 
                                      1= Complete Remission- No Surgery, 
                                      2= Surgery for Residual or Recurrent Disease 

































          1. Complete Remission (CR) at Assessment ± No Surgery 
          3. Progressive Disease ± No Surgery 
          4. Residual Disease at Assessment ± Surgery 






           















Fig 5b                                Survival by TNM Stage 
 
 
